Research
Hormonal
Dual agonists targeting GLP-1 and PYY3–36 may produce synergistic effects for weight loss.
Consider dual agonist therapies for enhanced weight loss efficacy.
StrongSupportsmedium confidence
As dual agonists targeting GLP-1 and PYY3–36 may produce synergistic effects, they can be effective at lower doses.
Why this rating
The claim is based on current research findings regarding dual agonists.
Source
Neurocircuitry underlying the actions of glucagon-like peptide 1 and peptide YY3–36 in the suppression of food, drug-seeking, and anxiogenesis
Yasmina Dumiaty et al. · Neuropeptides · 2024
DOI 10.1016/j.npep.2024.102427
reviewCited 7×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →